TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of volunteers protected against CL (absence of a lesion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of racemic tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of TPN171H
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of TPN171H
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mayo Elbow Performance Score (MEPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical improvement in AST/ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in LSM (Liver Stiffness Measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in CAP (Controlled Attenuation Parameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Long-term safety of Tramiprosate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functional vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post Thrombotic Syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in urine melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Patients With Dichotomous Outcome Agreement in Diagnosis of H. Pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway trauma incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Change From Baseline in Brain Magnetic Resonance Imaging (MRI) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plasma Concentration of PF-04360365
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to Pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal butyrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Use of Hearing Assistance Device (HAD) During Emergency Department (ED) Stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During ED Stay
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-Rated Quality of Post-Discharge Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical efficacy of topical therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Evolution of the calcific deposit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Toxicity Related to Electrochemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrosis Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density and strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Inspiratory muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infection cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity and Specificity of 68Ga-RM2 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value of 68Ga-RM2 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative Predictive Value of 68Ga-RM2 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: accuracy of respiratory rate in breaths per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Protection
Endpoint domain: Adverse events/effects
Primary endpoint: Histological tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of skin neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Referrals to Health Promotion and Disease Prevention Services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Moderate Intensity Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Leading to Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Architecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear or Almost Clear at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait velocity (m/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stride length (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cadence (steps/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature of observed abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progress to End Stage Renal Disease
Endpoint domain: Mortality/survival
Primary endpoint: double of serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Overall Global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Motivation for change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drinks per occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in PANSS sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in Clinical Global Improvement Scale (CGIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Home Dialysis Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from active phase to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Positive response to Mannitol challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Magnetic stimulation pressure measure (Pstim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Oxygen saturation of Vastus lateralis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic marker in HNSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical attenuation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: degree of post-hernioplasty acute and chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parenteral/oral analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tobacco quit rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Disease activity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of diameter X severity for affected areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infliximab level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in percent days of HHV-8 detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quantitative reduction in HHV-8 DNA detected by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Metabolomic profile of urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EC50 for Successful Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform intra-operative mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Rabies Virus Neutralizing Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of hA20
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance of hA20
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of hA20
Endpoint domain: Adverse events/effects
Primary endpoint: Identify symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to cure with corneal epithelial defect closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of study medication use compared to control medications
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change from baseline in depressive-symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Compliance with remote follow-ups
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Promotion and tracking of healthy lifestyle changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Percent Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CO2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Amplitude of Glucose Excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caries Activity and Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective and subjective measures of degree of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective measures of physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective measures of functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-stage renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 50% reduction of creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Performance on the eye tracking measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in School Attendance - Registry data
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in School Attendance - Self-reported data
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum tolerated dose of talazoparib (three day schedule)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of talazoparib (seven day schedule)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily preoperative walking activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose proportionality of clonidine MBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of clonidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in family communication time
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in perceived communication adequacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in family harmony
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deep Infection in the target fracture site
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic-assessed bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone Gain or Loss in Millimeters (Buccopalatal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Bone Gain or Loss in Millimeters (Mesiodistal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Bone Gain or Loss in Millimeters (Stent to Apex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Appetite Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the MK-8266 Concentration Versus Time Curve AUC(0-8 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of MK-8266
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline Immunology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EGFR Mutation Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Isokinetic strength testing (peak torques)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Isokinetic strength testing (ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Significant Shoulder Injury (SSI) collection (time lost from participation)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical clotting in the air trap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HbA1c (glycaemic haemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting plasma glucose (FBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum Neuropeptide Y levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who discontinued from the study
Endpoint domain: Adverse events/effects
Primary endpoint: levels of soluble intercellular adhesion molecule 1 (sICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukocyte integrin ß2 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood-Brain Barrier (BBB) Permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum effective volume of local anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia diagnosis in fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Balance and Lateral Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change rate from baseline in Low Density Lipoprotein-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Mean Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum thromboxane B2 (TXB2) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite rate of adverse clinical/device events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3/4/5 Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: motor unit firing rate characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goligher score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in hs CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MCP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Maximal Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention on buprenorphine treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sexual outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinical outcome of cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological response (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score Alouette reading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score EVALEC reading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score silence reading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of reading comprehension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of Khomsi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute and chronic cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased Expression of Full-length Type VII Collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With New or Increased Numbers of Anchoring Fibrils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Absence of Gentamicin Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: uniaxial biomechanical analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Modified Vesikari Scale Score >=9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS score in patients with Basilar Artery Occlusion Stroke after 24-hour admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Survival rate in patients with Basilar Artery Occlusion Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Mean drop in hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CCSIO scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of POC urine culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of POCT Flexicult ID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose dynamics and insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of soluble ST2 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes